Ketoconazole enantiomer for the treatment of diabetes mellitus

Bibliography

• United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKDPS 33) Lancet 1998;356:837-53
   Google Scholar
• Holman RR, Paul SK, Bethel MA, 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Chalmers, J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359:1618-20
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patient with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-390
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Outcomes and Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Engl J Med 2008;58:2560-72
   Google Scholar
• Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19(4):477-90
   PubMed Web of Science ®Google Scholar
• Friedman TC, Mastorakos G, Newman TD, Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 1996;43(6):645-55
   PubMed Web of Science ®Google Scholar
• Walker BR. Cortisol – cause and cure for metabolic syndrome? Diabet Med 2006;23:1281-88
   PubMed Web of Science ®Google Scholar
• Andrews R, Phillips DIW, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998;83:1806-9
   PubMed Web of Science ®Google Scholar
• Marinello B, Ronconi V, Rilli S, Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and cushing's syndrome. Eur J Endocrinol 2005;155:435-41
   Web of Science ®Google Scholar
• Stulnig TM, Waldhausl W. 11β-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 2004;47:1-11
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Stewart PM. Modulation of glucocorticoid action and the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21(4):607-19
   PubMed Web of Science ®Google Scholar
• Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes and obesity. Expert Opin Investig Drugs 2008;17(4):481-96
   PubMed Web of Science ®Google Scholar
• Morton NM, Holms MC, Fievet C, Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol Chem 2001;276:41293-300
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Paterson J, Shinyama H, A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;194:2166-70
   Web of Science ®Google Scholar
• Paulmyer-Lacroix O, Boullu S, Oliver C, Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002;87:2701-5
   PubMed Web of Science ®Google Scholar
• Kerstens MN, Riemens SC, Sluiter WJ. Lack of relationships between 11beta-hydroxysterod dehydrogenase set point and insulin sensitivity in the basal state and after 24h insulin infusion in healthy subjects and type 2 diabetic patients. Clin Endocrinol (Oxf) 2000;52:403-11
   PubMed Web of Science ®Google Scholar
• Andrews RC, Rooyackers O, Walker BR. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285-91
   PubMed Web of Science ®Google Scholar
• Liu, JK, Fleseriu M, Delashaw JB, Treatment options for cushings disease after unsuccessful transsphenoidal hypophysectomy. Neurosurg Focus 2007;23(3):E8-15
   PubMedGoogle Scholar
• Sonino N, Boscaro M, Paoletta A. Ketoconazole treatment in cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991;35:347-52
   PubMed Web of Science ®Google Scholar
• Fallo F, Paoletta A, Tona F, Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in cushing's syndrome. J Inter Med 1993;234:595-8
   PubMed Web of Science ®Google Scholar
• Dunmire D, Freedman TB, Hafie LA, Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism. Chirality 2005;17:S101-8
   PubMed Web of Science ®Google Scholar
• Dilmaghanian S, Gerber JG, Filler SG, Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates. Chirality 2004;16:79-85
   PubMed Web of Science ®Google Scholar
• Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. Stereoisomers of ketoconazole: Preparation and biological activity. J Med Chem 1992;35:2818-25
   PubMed Web of Science ®Google Scholar
• Diederich S, Grossmann C, Hanke B, In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenase (11β–HSDs): chenodeoxycholic acid selectively inhibits 11β–HSD-1. Eur J Endocrinol 2000;142:2007
   Google Scholar
• Boudriau S, Demnati R, Swearingen D, Differential effects of co-administration of racemic ketoconazole and levdexketoconazole on the pharmacokinetic profile of atorvastatin. Clin Pharmacol Ther 2008;83(1):S88
   Google Scholar
• Park J-Y, Kim K-A, Shin J-C, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 2004;58(4):397-402
   PubMed Web of Science ®Google Scholar
• Schwartz SL, Rendell M, Ahmann AJ, Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. Clin Ther 2008;30:1081-8
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Ratner RE, Han J, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MJ, Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008;31:1-11
   Web of Science ®Google Scholar
• Rosenstock J, Banarer S, Fonseca V, Efficacy and safety of the 11-β-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes. Diabetes 2009;58(Suppl 1): 7-LB, LB3
   Google Scholar